Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atogepant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL known ✓ | Q16602 | 20/20 | 1.00 |
| ▸ | RAMP1 | O60894 | 13/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atogepant SCHEMBL19750880 | 1.00 | CALCRL (1.00) | CALCRLRAMP1 | |
| Atogepant SCHEMBL30603188 | 1.00 | CALCRL (1.00) | CALCRLRAMP1 | |
| Atogepant SCHEMBL4570348 | 1.00 | CALCRL (1.00) | CALCRLRAMP1 | |
| Atogepant SCHEMBL22259545 | 1.00 | CALCRL (1.00) | CALCRLRAMP1 | |
| Atogepant SCHEMBL31611055 | 1.00 | CALCRL (1.00) | CALCRLRAMP1 | |
| Atogepant SCHEMBL16652662 | 0.99 | CALCRL (0.99) | CALCRLRAMP1 | |
| Atogepant SCHEMBL16653283 | 0.99 | CALCRL (0.99) | CALCRLRAMP1 | |
| Atogepant SCHEMBL16653020 | 0.99 | CALCRL (0.99) | CALCRLRAMP1 | |
| Atogepant SCHEMBL35210098 | 0.99 | CALCRL (0.99) | CALCRLRAMP1 | |
| Atogepant SCHEMBL16652952 | 0.99 | CALCRL (0.99) | CALCRLRAMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 288 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130901-A1 | CGRP RECEPTOR ANTAGONIST FOR THE TREATMENT OF MIGRAINE | ALLERGAN PHARMACEUTICALS INT LTD (IE) | 2026-05-14 | — | — | US | claimed |
| US-12622897-B2 | Methods of treating migraine | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2026-05-12 | — | — | US | claimed |
| WO-2026090164-A1 | COMPOSITIONS COMPRISING ELISMETREP AND A SECOND THERAPEUTIC AGENT FOR TREATING OR PREVENTING MIGRAINE OR PAIN | KALLYOPE, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4719347-A1 | SPRAY-DRIED COMPOSITIONS COMPRISING CGRP RECEPTOR ANTAGONISTS | Orexo AB (SE) | 2026-04-08 | — | — | EP | claimed |
| US-20260091031-A1 | CGRP RECEPTOR ANTAGONISTS FOR TREATING CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) | CHIARUGI ALBERTO (IT) | 2026-04-02 | — | — | US | claimed |
| EP-4698530-A1 | NK3 MODULATORS AND USES THEREOF | Kallyope, Inc. (US) | 2026-02-25 | — | — | EP | claimed |
| US-20260014127-A1 | METHODS OF TREATING MIGRAINE | ALLERGAN PHARMACEUTICALS INT LTD (IE) | 2026-01-15 | — | — | US | claimed |
| US-12521389-B2 | Therapeutic approach to lung disease | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-13 | — | — | US | claimed |
| US-20260001944-A1 | METHODS OF TREATING PAIN CAUSED BY A BONE FRACTURE | UNIV INDIANA TRUSTEES (US) | 2026-01-01 | — | — | US | claimed |
| US-20260001942-A1 | TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO | H LUNDBECK AS (DK) | 2026-01-01 | — | — | US | claimed |
| US-20220305088-A1 | METHODS AND COMPOSITIONS FOR TREATING A MICROBIAL INFECTION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-09-29 | — | — | US | claimed |
| WO-2022185224-A1 | TREATMENT AND/OR REDUCTION OF OCCURRENCE OF MIGRAINE | HASLETON MARK (IL) | 2022-09-09 | — | — | WO | claimed |
| US-20220249471-A1 | NEW THERAPEUTIC APPROACH TO LUNG DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-11 | — | — | US | claimed |
| EP-4034156-A1 | COMBINATION THERAPY WITH CGRP ANTAGONISTS | Allergan Pharmaceuticals International Limited (IE) | 2022-08-03 | — | — | EP | claimed |
| EP-4027984-A1 | COMBINATION THERAPY FOR THE TREATMENT OF MIGRAINES | The University of Chicago (US) | 2022-07-20 | — | — | EP | claimed |
| WO-2022132989-A1 | COMPOSITIONS FOR IMPROVED DELIVERY OF CGRP INHIBITORS | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2022-06-23 | — | — | WO | claimed |
| WO-2022109077-A1 | COMPOSITIONS FOR IMPROVED DELIVERY OF CGRP INHIBITORS | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2022-05-27 | — | — | WO | claimed |
| EP-3969054-A1 | OIL-SOLUBLE DRUG CONTAINING COMPOSITIONS AND METHODS OF USE THEREOF | Aegis Therapeutics, LLC (US) | 2022-03-23 | — | — | EP | claimed |
| EP-3956025-A1 | CGRP ANTAGONISTS FOR THE TREATMENT OF MEDICATION OVERUSE HEADACHE, POST-TRAUMATIC HEADACHE, POST-CONCUSSION SYNDROME AND VERTIGO | Allergan Sales, LLC (US) | 2022-02-23 | — | — | EP | claimed |
| US-20220031686-A1 | Treatment of Migraine | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2022-02-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622897-B2 | Methods of treating migraine | SLC6A2, SLC18A2, SLC28A2 | CALCRL 242/4885RAMP1 232/4885 |
| US-20220031686-A1 | Treatment of Migraine | VASP, SCN10A, PDE3A | CALCRL 339/4885RAMP1 554/4885 |
| US-20260001944-A1 | METHODS OF TREATING PAIN CAUSED BY A BONE FRACTURE | OPRL1, CALCRL, OPRK1 | CALCRL 2/4885RAMP1 85/4885 |
| US-20260091031-A1 | CGRP RECEPTOR ANTAGONISTS FOR TREATING CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) | CALCRL, GRPR, OPRL1 | CALCRL 1/4885RAMP1 109/4885 |
| US-20260001942-A1 | TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO | CDR2, OPRL1, TPH1 | CALCRL 4/4885RAMP1 140/4885 |
| US-20260014127-A1 | METHODS OF TREATING MIGRAINE | CYP2D6, CYP3A43, CYP3A5 | CALCRL 3139/4885RAMP1 274/4885 |
| US-20260130901-A1 | CGRP RECEPTOR ANTAGONIST FOR THE TREATMENT OF MIGRAINE | PTGDR, GRPR, CALCRL | CALCRL 3/4885RAMP1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.